weight loss, food and drug administration

Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
Compound versions of some weight loss drugs to be restricted
Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for weight loss, as is permissible by the FDA.
How weight-loss drugs could help treat addiction, arthritis, more
Popular weight-loss drugs like Ozempic and Wegovy are known for helping people who are looking to shed some pounds, but research suggests they could offer other life-changing benefits. Dr. Natalie Azar joins TODAY to talk about some of the clinical trials and the potential benefits on issues including sleep apnea,
Ending of US weight-loss drug shortages prompts compounder complaints
Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US, according to the US Food and Drug Administration (FDA). That means that compounding pharmacies and outsourcing facilities that had been legitimately preparing their own versions of the drugs will no longer be permitted to do so.
Who can get weight loss drugs on the NHS in Scotland?
The medicines watchdog has agreed the drugs are safe and cost-effective for NHS use. Last year, semaglutide was approved for treating obesity under the brand name Wegovy. It has also been licensed under the brand name Ozempic for treating diabetes in some circumstances,
Compound versions of weight loss drugs will no longer be available, FDA rules
Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available after a decision by the U.S. Food and Drug Administration. The agency has ordered compounding pharmacies to stop making compound versions of GLP-1 drugs now that the drugs are no longer in short supply.
Medications For Weight Loss
Dr. Alexandro Zarruk, MD, MSc., FACP, FRCPC, Internal Medicine, talks about medications that can help patients lose weight.
Patients, doctors voice frustration over restricted access to weight loss drugs
A federal judge’s ruling restricts compounding pharmacies from producing generic Zepbound, sparking concerns over affordability
Ozempic users say their exes are attempting to reconnect with them after weight loss: ‘Second chance at love’
It’s an unexpected Ozempic side effect. Slimmed-down users of GLP-1 drugs say their exes have started sliding into their DMs ...
Ozempic vs Metformin For Weight Loss: Weighing the Pros & Cons of Each
The increasing popularity of weight loss drugs like Wegovy, Ozempic, Mounjaro and metformin may have you wondering how all ...
New Discovery Promises Weight Loss Without Ozempic's Side Effects
Stanford Medicine researchers have identified a naturally occurring molecule that mimics the appetite-suppressing effects of ...
Natural alternative to Ozempic made mice eat up to 50% less — without side effects
Scientists have discovered a naturally-occurring molecule that rivals the weight-loss effects of semaglutide-based GLP-1s like Ozempic in animals.
Employers face pressure to add coverage of Ozempic, other weight-loss drugs
Why some health groups are banding together to push for a range of obesity-care options in workplace-sponsored insurance.
The rise of the Ozempic menu and how weight-loss drugs are changing dining out
With more diners skipping mains, drinking less and sharing starters because of weight-loss drugs, the traditional ...
New York Post4d
We went blind after using weight-loss drugs like Ozempic and Mounjaro
When James Norris, a 56-year-old mechanic from Roxbury, New Jersey, went on a low dose of Mounjaro, a GLP-1 medication similar to Ozempic, to lose weight in March 2023, he thought it would be a ...
Roche takes big step in weight-loss field with $5.3 billion deal.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...